9540 Federal Register / Vol. 72, No. 41 / Friday, March 2, 2007 / Notices 

Tool for the development of MATERbased contraceptives. 

Market: Approximately 10% of 

women of reproductive age experience 

infertility, and approximately 5% per 

year experience menstrual irregularity. 

Development Status: Established 

research test, ready for additional 

clinical research and commercial 

development. 

Inventors: Lawrence M. Nelson and 

Zhi-Bin Tong (NICHD). 

Publications: 

1. Zhi-Bin Tong et al. A mouse gene 

encoding an oocyte antigen associated 

with autoimmune premature ovarian 

failure. Endocrinology. 1999 

Aug;140(8):3720–3726. 

2. Zhi-Bin Tong et al. Developmental 

expression and subcellular localization 

of mouse MATER, an oocyte-specific 

protein essential for early development. 

Endocrinology. 2004 Mar;145(3):1427–

1434. 

3. Zhi-Bin Tong et al. A human 

homologue of mouse Mater, a maternal 

effect gene essential for early embryonic 

development. Hum Reprod. 2002 Apr; 

17(4):903–911. 

4. Zhi-Bin Tong et al. Mater, a 

maternal effect gene required for early 

embryonic development in mice. Nat 

Genet. 2000 Nov;26(3):267–268. 

Patent Status: 

1. PCT Application No. PCT/US01/ 

10981 filed 04 Apr 2001, which 

published as WO02/032955 on 25 Apr 

2002 (HHS Reference No. E–239–2000/ 

0-PCT–02). 

2. U.S. Application No. 10/399,443 

filed 16 Apr 2003 (allowed) (HHS 

Reference No. E–239–2000/0-US–03). 

3. U.S. Application No. 11/586,160 

filed 24 Oct 2006 (HHS Reference No. 

E–239–2000/0-US–08). 

4. U.S. Application No. 11/586,075 

filed 24 Oct 2006 (HHS Reference No. 

E–239–2000/0-US–09). 

5. U.S. Application No. 10/677,943 

filed 01 Oct 2003 (allowed) (HHS 

Reference No. E–239–2000/1-US–02). 

6. Foreign counterparts pending in 

Australia, Canada, Europe, and Japan. 

Licensing Availability: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Tara L. Kirby, 

Ph.D.; 301/435–4426; 

tarak@mail.nih.gov. 

Dated: February 26, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–3694 Filed 3–1–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Identification and Isolation of the 

Receptor for Pigment EpitheliumDerived Factor (PEDF) 

Description of Technology: This 

application describes and claims 

compositions and methods related to 

PEDF-R, a receptor for pigment 

epithelium-derived factor (PEDF). PEDF 

(aka serpin f1 gene product) is a protein, 

belonging to the serpin superfamily 

with neurotrophic, gliastatic, 

neuronotrophic, antiangiogenic, and 

antitumorigenic properties. However, 

PEDF lacks the characteristic ability of 

serpins to inhibit serine protease 

activity. In particular, the compositions 

and methods described and claimed in 

this application are related to the 

isolation, cloning, expression and 

characterization of a receptor for PEDF, 

PEDF-R. The PEDF-R gene (also known 

as TTS-2.2, iPLA-zeta, ATGL, desnutrin, 

or PNPLA2) is located on chromosome 

11. The sequence of the PEDF-R 

polypeptide is composed of 504 amino 

acids, and shares homology with other 

genes such as for adiponutrin and GS2, 

contains a patatin-like phospholipase 

A2 domain and up to four 

transmembrane regions. PEDF-R 

exhibits a potent phospholipase A2 

activity, binds to PEDF ligands with 

high affinity, and it localizes to plasma 

membranes. An extracellular loop 

region is available for the interactions 

with extracellular PEDF ligand, which 

stimulate the phospholipase activity of 

PEDF-R. The identification of this novel 

PEDF-R gene in the retina for a 

phospholipase-linked membrane 

protein with high affinity for PEDF, 

suggests a molecular pathway by which 

ligand/receptor interaction on the cell 

surface could generate a cellular signal. 

Applications: 

1. Basic research to further elucidate 

the role of PEDF and its receptor in 

signal transduction pathways. 

2. Development of drug screening 

assays to identify agonists and 

antagonists of PEDF activity. 

3. Development of new biological 

molecules to regulate PEDF signaling 

such as monoclonal antibodies and 

chimeric IgG-receptor constructs. 

Development Stage: Information on 

research being conducted in Dr. 

Becerra’s laboratory can be found on the 

Internet at http://www.nei.nih.gov/ 

intramural/protein_struct_func.asp. The 

ability of the receptor or receptortargeted molecules and biologics to be 

used as therapeutics remains the subject 

of early research and development 

efforts. 

Inventors: S. Patricia Becerra (NEI), 

Luigi Notari (NEI), Jorge Laborda 

(CDER/FDA), et al. 

Publications: 

1. The patent application has been 

published as WO 2005/014645 A2 on 17 

Feb 2005. 

2. L Notari et al. Identification of a 

lipase-linked cell membrane receptor for 

pigment epithelium-derived factor. J 

Biol Chem. 2006 Dec 8; 281(49):38022–

38037. 

Patent Status: 

1. U.S. Patent Application No. 10/ 

566,540 filed 16 Oct 2006, entitled 

‘‘PEDF-R Receptor and Uses,’’ is 

pending (HHS Reference No. E–314–

2003/2–US–02). The U.S. Application 

has not been published. Only U.S. 

Patent protection has been sought for 

this technology. There are no foreign 

counterpart patent applications. 

2. PCT/US2004/025560 filed 05 Aug 

2004 and published as WO 2005/014645 

A2 on 17 Feb 2005, now expired (HHS 

Reference No. E–314–2003/2–PCT–01). 

3. U.S. Provisional Application No. 

60/579,177 filed 12 Jun 2004, now 

abandoned (HHS Reference No. E–314–

2003/1–US–01). 

4. U.S. Provisional Application No. 

60/493,713 filed 07 Aug 2003, now 

abandoned (HHS Reference No. E–314–

2003/0–US–01). 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 72, No. 41 / Friday, March 2, 2007 / Notices 9541 

Biological Materials Availability: 

Biological materials related to this 

technology are not available at this time. 

Licensing Availability: This 

application is available for license on a 

non-exclusive or exclusive basis. 

Licensing Contact: Susan S. Rucker; 

301/435–4478; e-mail: 

ruckersu@mail.nih.gov. 

Genes Expressed in Prostate Cancer 

and Methods of Use 

Description of Technology: This 

invention is a novel gene, called New 

Gene Expressed in Prostate (NGEP). 

This gene appears to be expressed only 

in human prostate and prostate cancer. 

This gene has two known splice variants 

of significantly different size. The 

shorter splice variant encodes a 

cytoplasmic protein, while the longer 

splice variant encodes a plasma 

membrane protein, which has been 

detected on the plasma membrane of 

human cancer cells. 

This patent application contains 

claims to the polypeptide, NGEP, 

nucleotides encoding NGEP, antibodies 

that bind NGEP polypeptides, and 

methods of using these polypeptides, 

polynucleotides, and antibodies. 

The presence of the protein on the 

cell surface and the selective expression 

in prostate and prostate cancer make 

this a potential target for prostate cancer 

diagnostics and therapeutics. Potential 

therapeutics could be gene-based, 

vaccines, antibodies, or 

immunoconjugates. 

Inventors: Ira Pastan, Tapan Bera, and 

Byungkook Lee (NCI.) 

Publications: 

1. S Das et al. NGEP, a prostatespecific plasma membrane protein that 

promotes the association of LNCaP cells. 

Cancer Res. 2007 Feb 15; 67(4):1594–

1601. 

2. TK Bera et al. NGEP, a gene 

encoding a membrane protein detected 

only in prostate cancer and normal 

prostate. Proc Natl Acad Sci USA. 2004 

Mar 2; 101(9):3050–3064. 

Patent Status: 

1. U.S. Provisional Application No. 

60/461,399 filed 08 Apr 2003 (HHS 

Reference No. E–148–2003/0–US–01). 

2. PCT Application No. PCT/US04/ 

10588 filed 05 Apr 2004, which 

published as WO 2004/092213 on 28 

Oct 2004 (HHS Reference No. E–148–

2003/0–PCT–02). 

3. U.S. Patent Application No. 10/ 

552,515 filed 06 Oct 2005 (HHS 

Reference No. E–148–2003/0–US–03). 

Licensing Status: Available for nonexclusive licensing. 

Licensing Contact: Jesse S. Kindra, 

J.D.; 301/435–5559; 

kindraj@mail.nih.gov. 

Dated: February 22, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–3695 Filed 3–1–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Office of AIDS Research Advisory 

Council. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: Office of AIDS 

Research Advisory Council. 

Date: April 19, 2007. 

Time: 9 a.m. to 5 p.m. 

Agenda: The meeting will focus on HIVrelated Complications including 

Malignancies, Cardiovascular Disease, and 

Metabolic Complications. An update will be 

provided on the OARAC Working Groups for 

Treatment and Prevention Guidelines. 

Place: National Institutes of Health, 5635 

Fishers Lane, Rockville, MD 20852. 

Contact Person: Christina Brackna, 

Coordinator, Program Planning and Analysis, 

Office of Aids Research, Office of the 

Director, NIH, 5635 Fishers Lane MSC 9310, 

Suite 4000, Rockville, MD 20852, (301) 402–

8655, cm53v@nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

Information is also available on the 

Institute’s Center’s home page: http:// 

www.ni.gov/od/oar/index.htm, where an 

agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: February 23, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–961 Filed 3–1–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Meeting: Secretary’s 

Advisory Committee on Genetics, 

Health, and Society 

Pursuant to Public Law 92–463, 

notice is hereby given of the twelfth 

meeting of the Secretary’s Advisory 

Committee on Genetics, Health, and 

Society (SACGHS), U.S. Public Health 

Service. The meeting will be held from 

8 a.m. to approximately 5 p.m. on 

Monday, March 26, 2007 and 8 a.m. to 

approximately 5 p.m. on Tuesday, 

March 27, 2007, at the Marriott Inn and 

Conference Center, University of 

Maryland—College Park, 3501 

University Boulevard East, Adelphi, MD 

20783. The meeting will be open to the 

public with attendance limited to space 

available. The meeting also will be Web 

cast. 

The agenda will focus on the 

oversight of genetic testing, including 

the role of the private sector in assuring 

the quality and validity of genetic tests; 

the impact of gene patents and licensing 

practices on patient access to genetic 

technologies, including a progress 

report on the Committee’s study; and 

the status of Federal genetic information 

nondiscrimination legislation. The 

Committee will be briefed on the 

Secretary’s Personalized Health Care 

Initiative and the work of the American 

Health Information Community, 

particularly its Personalized Health Care 

Working Group. The Committee’s report 

on the Policy Issues Associated with 

Undertaking a New Large U.S. 

Population Cohort Project on Genes, 

Environment and Disease will be 


pwalker on PROD1PC71 with NOTICES